Eyecare specialist Bausch Health Companies(NYSE: BHC) wasn't a clear winner on the stock exchange Thursday, to put it charitably. After unveiling its latest earnings report it was met with a sell-off, as investors drove its share price down by over 7%. That was out of sync with the generally positive sentiment on equities that day, as the S&P 500 index posted a gain of 0.9%.
Investors not pleased with revenue growth and narrowed loss
Although Bausch management put a positive spin on the company's first quarter, the earnings release featured a few numbers that just didn't look very pretty.
It earned revenue of $2.15 billion, and although this was up by 11% year over year, it matched the average estimate of analysts following the stock. The company managed to narrow its net loss based on generally accepted accounting principles (GAAP) to $64 million ($0.17 per share) from the first-quarter 2023 shortfall of $201 million, which was undoubtedly an accomplishment. Yet it wasn't anywhere near the $0.69 per-share profit those pundits were collectively modeling.
Another positive the market did not appreciate was that all of Bausch's operating segments posted gains in revenue. This was led by its foundational Bausch + Lomb unit; it saw an 11% increase, matching that of total revenue.
2024 guidance reaffirmed
Bausch also reaffirmed its guidance for full-year 2024. It stated again that it's expecting revenue of $9.30 billion to $9.55 billion for the year, with non-GAAP (adjusted) earnings before interest, taxes, depreciation, and amortization (EBITDA) of $3.20 billion to $3.35 billion. It did not provide a bottom-line forecast.
On average, analysts tracking Bausch stock are anticipating $9.39 billion for annual revenue.
Should you invest $1,000 in Bausch Health Companies right now?
Before you buy stock in Bausch Health Companies, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bausch Health Companies wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than tripled the return of S&P 500 since 2002*.
*Stock Advisor returns as of April 30, 2024
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Bausch Health Companies. The Motley Fool has a disclosure policy.
